Athira Pharma
Bothell, Washington, United States · Biotechnology, Health Care, Pharmaceutical · 135 employees
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration.
Funding history
- Funding Round — $90.0M — Dec 2025
- Venture - Series Unknown — $89.0M — Jun 2020
- Venture - Series Unknown — $3.8M — Jan 2020
- Seed — $1.3M — Dec 2018
- Venture - Series Unknown — $14.1M — Nov 2017
Recent signals
- Feb 03, 2026: LeonaBio Appoints Mark F. Kubik as Chief Business Officer
- Dec 18, 2025: Raised $90.0M in Funding Round
- Nov 06, 2025: SEC 8-K (2.01): On November 6, 2025, Athira Pharma, Inc. announced its financial results for the quarter ended September 30, 2025. This filing represents the completion of the financial reporting process for the quarter, which highlights the company's operational performance and financial condition. The press release may contain important insights into revenue, expenses, and net income that influence investor perception and stock performance. Given the timing of this report, it reflects recent strategic developments and management's analysis of the company's performance over the last quarter.
- Apr 15, 2024: Athira Pharma Appoints Javier San Martin as Chief Medical Officer
- Jun 12, 2020: Raised $89.0M in Venture - Series Unknown
- Jan 24, 2020: Raised $3.8M in Venture - Series Unknown
- Dec 20, 2018: Raised $1.3M in Seed
- Nov 01, 2017: Raised $14.1M in Venture - Series Unknown
See plans & pricing → Track Athira Pharma’s funding, hiring, and signals — with verified contacts — on Fundz.